• Kraig Biocraft Laboratories posted a net loss of USD 942,720 for quarter ended March 31, 2026, widening 57.11% year over year.
• Operating loss widened 42.21% to USD 825,500 as operating expenses climbed 42.21% to USD 825,500.
• General and administrative expense rose 60.45% to USD 495,566, while research and development spending more than doubled to USD 66,701.
• Cash and cash equivalents increased to USD 2.89 million, while working capital deficit narrowed to USD 7.67 million.
• Company issued 45,384,194 shares for USD 4.12 million under its standby equity purchase agreement as of March 31, 2026, with proceeds earmarked for working capital and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kraig Biocraft Laboratories Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023130), on May 14, 2026, and is solely responsible for the information contained therein.